The arteriovenous graft function has been addressed and to this end, Biomodics (BM) has established a reactor to manufacture the grafts to be tested. The in-vivo aging test has been initiated as planned under the lead of Region Syddanmark (OUH) and the integration and performance are being monitored until removal of the grafts. In parallel, tissue integration is being tested by partner VERIGRAFT. In-vitro evaluations are also being conducted by Biomodics notably to test early cannulation and resistance to kinking. University of Birmingham (BHAM) is working towards establishing appropriate fluid dynamic modelling for simulations of blood flow in the graft.
The diagnostic tools and telemonitoring that will be developed in TeleGraft are being addressed by the partners Leibniz-Institut Fuer Photonische Technologien E.V (IPHT), OUH and BMD Software LDA (BMD). Under the lead of IPHT, the hardware for sensor and data collection is being analysed and the Raman spectrometer hardware is being developed. From this work and research, the standardization procedure is being developed for the analysis of the collected data and AI modeling. From these tasks, partner BMD is developing a data presentation software and easy to understand monitoring dashboard.
This work aims at preparing for the next phase of the project, the clinical evaluation of TeleGraft.
In addition, and as part of its communication and dissemination plan, the consortium has also been active in communication about the project, focusing on increasing its visibility towards its target audiences and partners at various events and online via its website and social media accounts. The exploitation plan of the project has been drafted and will frame the discussion on how the project´s results will be further utilized as TeleGraft and its component are being developed. Lastly, the regulatory pathway has been defined in its first version to prepare for the approval of TeleGraft when time comes.
